NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: GFOR) is a clinical-stage biopharmaceutical company developing natural killer (NK) cell-based immunotherapies for oncology and neurodegenerative diseases, including Alzheimer's disease. The company entered the public markets through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Global Corp. that completed its SPAC IPO in 2022. The de-SPAC merger closed in 2023, giving NKGen Biotech its Nasdaq listing. The company filed a Form 8-K with the SEC on February 25, 2025. For full filing history, deal terms, and real-time SPAC analytics on NKGen Biotech and thousands of other transactions, sign up for SpacDesk.